PhRMA and BMS stock rise on FDA stability outlook

Shares of PhRMA constituents, particularly Bristol Myers Squibb, rise within 3 months as the FDA commissioner appointment reduces regulatory uncertainty. The industry's lobbying efforts against pricing policies contribute to investor confidence.

Implied probability (Yes)

65%